ImmuPharma PLC - London-based specialist drug discovery and development company - Says its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases has yielded data that provides novel insights into autoimmune mechanisms. P140, the firms lead programme, is a unique non-immunosuppressive peptide for the treatment of systemic lupus erythematosus and chronic idiopathic demyelinating polyneuropathy. Adds that the findings, which were discovered by its R&D subsidiary ImmuPharma Biotech, pave the way for better diagnostics, identifying patients most likely to respond to P140 therapy and improved patient monitoring. Says the research marks a ‘significant step towards personalised medicine in SLE and other autoimmune diseases.’ Details of the data findings are not being released at this time since they form part of the ongoing expansion of the firms intellectual property portfolio.
ImmuPharma Chief Executive Tim McCarthy says: ‘We are delighted to share these significant findings from ImmuPharma Biotech. This breakthrough research confirms our confidence in P140, its future therapeutic success and also creates potential new opportunities to strengthen our intellectual property portfolio, positioning us at the forefront of innovation in autoimmune disease therapies.’
Current stock price: 2.33 pence, up 94% on Thursday morning in London
12-month change: up 47%
Copyright 2025 Alliance News Ltd. All Rights Reserved.
